Imeglimin hydrochloride is primarily used in the treatment of type 2 diabetes. It works by improving insulin secretion from the pancreas, enhancing insulin sensitivity in peripheral tissues, and reducing excessive glucose production in the liver. This triple mechanism helps in achieving better blood glucose control. It is often prescribed as an oral medication, either as a monotherapy or in combination with other antidiabetic drugs, to manage blood sugar levels effectively. Its unique action on mitochondrial function also contributes to its efficacy in improving glycemic control while potentially offering protective effects on pancreatic beta cells. It is particularly beneficial for patients who require a well-tolerated option with a lower risk of hypoglycemia.